Falk Pettersson (mouthboard66)

Current challenges and opportunities to improving vitamin A status include lower VAS coverage among younger children (infants 6-11 months of age), finding ways to increase availability and access to dietary vitamin A sources, and ensuring local programme investments given the recent decentralization of the government. © 2020 The Authors. Maternal & Child Nutrition published by John Wiley & Sons Ltd.PURPOSE The diagnostic value of nomogram in pancreatic cancer (PC) with liver metastasis (PCLM) is still largely unknown. We sought to develop and validate a novel nomogram for the prediction of liver metastasis in patients with PC. METHOD About 604 pathologically confirmed PC patients from the Sun Yat-sen University Cancer Center (SYSUCC) between July, 2001 and December, 2013 were retrospectively studied. The SYSUCC cohort was randomly assigned to as the training set and internal validation set. Using these two sets, we derived and validated a prognostic model by using concordance index and calibration curves. Another two independent cohorts between August, 2002 and December, 2013 from the Sun Yat-sen Memorial Hospital (SYSMH, n = 335) and Guangdong General Hospital (GDGH, n = 503) was used for external validation. RESULT Computed tomography (CT) reported liver metastasis status, carcinoembryonic antigen (CEA) level and differentiation type were identified as risk factors for PCLM in the training set. The final diagnostic model demonstrated good calibration and discrimination with a concordance index of 0.97 and had a robust internal validation. BLU-945 The score ability to diagnose PCLM was further externally validated in SYSMH and GDGH with a concordance index of 0.93. The model showed better calibration and discrimination than CT, CEA and differentiation in each cohort. CONCLUSION Based on a large multi-institution database and on the routinely observed CT-reported status, CEA level and tumor differentiation in clinical practice, we developed and validated a novel nomogram to predict PLCM. © 2020 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.INTRODUCTION Efficacy and safety of abobotulinumtoxinA in adults with lower limb spasticity (LLS) are well-established. OBJECTIVE To examine safety and efficacy of abobotulinumtoxinA in patients previously treated with botulinum toxin type A (BoNT-A) products other than abobotulinumtoxinA. DESIGN Secondary analysis from a phase 3, double-blind, single-cycle, randomized, placebo-controlled study. SETTING 52 centers (11 countries). PATIENTS Adults with spastic hemiparesis were randomized (111) to receive abobotulinumtoxinA 1000 U, 1500 U or placebo in their affected lower limb. MAIN OUTCOME MEASURE(S) Muscle tone (6-point Modified Ashworth Scale [MAS], 0-5) for the gastrocnemius-soleus complex (GSC); proportion of MAS responders (≥1 point improvement); angle of catch (XV3 ) and spasticity grade (Y) for GSC and soleus. Assessments were at Weeks 1, 4, and 12 post-injection. Only descriptive statistics are presented. RESULTS Of 388 patients, 84 received previous BoNT-A treatment (abobotulinumtoxinA 1000 U N = 30; This article is protected by copyright. All rights reserved. This article is protected by copyright. All rights reserved.OBJECTIVE The aim of this study was to investigate whether the level, rate, and acceleration of BMI growth differ according to the presence or absence of adult cardiometabolic (CM) risks. METHODS BMI was measured in 1,000 Chileans at nine time points from birth to 23 years, and metabolic syndrome and its components were assessed at young adulthood. BMI growth was analyzed in the following three developmental periods birth to 6 months, 6 months to 5 years, and 5 to 23 years. RESULTS Individuals with CM risks had a specific constellation of early-life growth (faster growth after infancy, lower BMI decline approaching age 5, absence of a definitive BMI nadir in early childhood, higher 5-year BMI) and distinct young adu